CryoTherapeutics

CryoTherapeutics is an early-stage European innovator targeting the root cause of most heart attacks: vulnerable atherosclerotic plaque. Their implant-free cryotherapy technology cools plaque to -10°C to -20°C, aiming to stabilize it by reducing inflammation and increasing fibrous cap thickness, thereby lowering rupture risk. The company has completed a first-in-human (POLARSTAR) pilot study showing initial safety and feasibility, positioning it in a large, underserved cardiovascular market. Based in Leuven, Belgium, and founded in 2015, it is a private, pre-revenue company advancing a unique medical device platform.

Catheter-based cryotherapy system (CTS) consisting of a console and an intracoronary balloon catheter. Delivers controlled cryoenergy (-10°C to -20°C) to vulnerable coronary plaques to reduce inflammation and increase fibrous cap thickness, stabilizing the plaque and preventing rupture.

There are currently no FDA or CE-marked devices specifically indicated for vulnerable plaque stabilization, making CryoTherapeutics a potential first-mover. Competition exists indirectly from optimal medical therapy (drugs) and the off-label use of stents/drug-coated balloons, which are suboptimal for this indication. Other companies may be developing competing targeted local therapies.